| Primary |
| Product Used For Unknown Indication |
34.1% |
| Dyspepsia |
28.7% |
| Abdominal Distension |
24.4% |
| Drug Use For Unknown Indication |
3.3% |
| Impaired Gastric Emptying |
1.9% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Nausea |
1.4% |
| Gastrointestinal Disorder |
1.1% |
| Vomiting |
0.8% |
| Analgesic Therapy |
0.4% |
| Diabetic Gastroparesis |
0.4% |
| Abdominal Pain |
0.3% |
| Depression |
0.3% |
| Diarrhoea |
0.3% |
| Prophylaxis |
0.3% |
| Anaesthesia |
0.3% |
| Epidural Anaesthesia |
0.2% |
| Gastritis |
0.2% |
| Hiv Infection |
0.2% |
| Tuberculosis |
0.2% |
|
| Tardive Dyskinesia |
72.4% |
| Extrapyramidal Disorder |
7.5% |
| Dyskinesia |
4.1% |
| Incorrect Drug Administration Duration |
2.5% |
| Tremor |
2.4% |
| Dystonia |
2.0% |
| Restless Legs Syndrome |
1.8% |
| Akathisia |
1.1% |
| Movement Disorder |
1.0% |
| Nervous System Disorder |
0.8% |
| Condition Aggravated |
0.6% |
| Parkinsonism |
0.6% |
| Visual Impairment |
0.6% |
| Serotonin Syndrome |
0.5% |
| Economic Problem |
0.4% |
| Mental Disorder |
0.4% |
| Suicidal Ideation |
0.4% |
| Activities Of Daily Living Impaired |
0.3% |
| Anxiety |
0.3% |
| Asthenia |
0.3% |
|
| Secondary |
| Product Used For Unknown Indication |
20.1% |
| Drug Use For Unknown Indication |
16.6% |
| Abdominal Distension |
11.9% |
| Dyspepsia |
11.9% |
| Nausea |
6.2% |
| Hypertension |
3.5% |
| Pain |
3.5% |
| Supplementation Therapy |
3.2% |
| Infection |
2.9% |
| Vomiting |
2.9% |
| Gastrooesophageal Reflux Disease |
2.1% |
| Drug Therapy |
2.0% |
| Gastrointestinal Disorder |
2.0% |
| Back Pain |
1.9% |
| Pancreatitis |
1.9% |
| Ill-defined Disorder |
1.6% |
| Abdominal Pain Lower |
1.5% |
| Abdominal Pain |
1.4% |
| Nutritional Support |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
|
| Tardive Dyskinesia |
66.7% |
| Nervous System Disorder |
8.3% |
| Extrapyramidal Disorder |
6.8% |
| Myocardial Infarction |
1.8% |
| Toxic Epidermal Necrolysis |
1.8% |
| Medication Error |
1.5% |
| Rhabdomyolysis |
1.5% |
| Vomiting |
1.5% |
| Multiple Injuries |
1.2% |
| Thrombocytopenia |
1.2% |
| Akathisia |
0.9% |
| Completed Suicide |
0.9% |
| Death |
0.9% |
| Malaise |
0.9% |
| Nausea |
0.9% |
| Respiratory Arrest |
0.9% |
| Tachycardia |
0.9% |
| Cardio-respiratory Arrest |
0.6% |
| Cerebral Haemorrhage |
0.6% |
| Coombs Positive Haemolytic Anaemia |
0.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
36.4% |
| Product Used For Unknown Indication |
13.8% |
| Prophylaxis |
7.7% |
| Nausea |
5.6% |
| Hypertension |
4.8% |
| Pain |
4.5% |
| Abdominal Pain |
3.0% |
| Non-small Cell Lung Cancer |
2.9% |
| Diffuse Large B-cell Lymphoma |
2.4% |
| Colorectal Cancer |
2.3% |
| Vomiting |
2.3% |
| Hiv Infection |
1.9% |
| Constipation |
1.9% |
| Surgery |
1.9% |
| Pneumocystis Jiroveci Pneumonia |
1.8% |
| Prostate Cancer |
1.6% |
| Colorectal Cancer Metastatic |
1.5% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Depression |
1.3% |
| Cough |
1.2% |
|
| Vomiting |
25.9% |
| Thrombocytopenia |
9.2% |
| Peripheral Motor Neuropathy |
6.7% |
| Sepsis |
5.6% |
| Weight Decreased |
5.6% |
| Diarrhoea |
5.3% |
| Nausea |
3.9% |
| Pulmonary Embolism |
3.9% |
| Urinary Tract Infection |
3.6% |
| Death |
3.3% |
| Hyponatraemia |
3.3% |
| Renal Failure Acute |
3.3% |
| Neutropenia |
3.1% |
| Pyrexia |
3.1% |
| Dehydration |
2.8% |
| Pneumonia |
2.5% |
| Cerebrovascular Accident |
2.2% |
| General Physical Health Deterioration |
2.2% |
| Neuropathy Peripheral |
2.2% |
| Optic Ischaemic Neuropathy |
2.2% |
|
| Interacting |
| Product Used For Unknown Indication |
24.0% |
| General Physical Health Deterioration |
16.0% |
| Depression |
12.0% |
| Alcohol Poisoning |
8.0% |
| Atrial Fibrillation |
8.0% |
| Atrial Flutter |
8.0% |
| Abnormal Behaviour |
4.0% |
| Drug Dependence |
4.0% |
| Major Depression |
4.0% |
| Mental Disorder |
4.0% |
| Staphylococcal Sepsis |
4.0% |
| Ventricular Arrhythmia |
4.0% |
|
| Drug Interaction |
22.2% |
| Hypotension |
22.2% |
| Asthenia |
11.1% |
| Dystonia |
11.1% |
| Electrocardiogram Qt Prolonged |
11.1% |
| Malaise |
11.1% |
| Therapeutic Response Increased |
11.1% |
|
